Rituximab and abatacept for rheumatoid arthritis.
Estimates from the UK indicate that around 0.5-1.0% of the population have rheumatoid arthritis. Here we assess the place of rituximab (MabThera--Roche Products Ltd) and abatacept (Orencia--Bristol-Myers-Squibb), drugs in two new classes, which are licensed for certain adults with the condition.
D000069594:Abatacept; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D018796:Immunoconjugates; D000069283:Rituximab; D000069594:Abatacept